Philips reports a 19% improvement in Adjusted EBITA to EUR 1 billion, net income of EUR 640 million and sales of EUR 7.2 billion in Q4, with the HealthTech portfolio growing at 5%. But still, there are worries about an investigation by the American Department of Justice representing the US Food and Drug Administration, arising from past inspections in and before 2015, focusing primarily on our external defibrillator business in the US. CEO Frans van Houten: “While discussions have not yet concluded, we anticipate a meaningful impact on the operations of this business.”

Read all the articles in our archive by becoming a member of Innovation Origins. Sign up here as a supporter of independent journalism!

Become a member!

On Innovation Origins you can read the latest news about the world of innovation every day. We want to keep it that way, but we can't do it alone! Are you enjoying our articles and would you like to support independent journalism? Become a member and read our stories guaranteed ad-free.

About the author

Author profile picture Bart Brouwers is co-founder and co-owner of Media52 BV, the publisher of